Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



GSK plc faces $300mn bet against it by Ken Griffin's Citadel

February 20, 2025
GSK plc, the UK-based pharmaceutical company, is facing a significant challenge as Ken Griffin's Citadel has placed a $300mn bet against it.
Citadel, a renowned investment firm, has expressed concerns about GSK's future prospects and has taken a bearish position on the company's stock. This move has caught the attention of investors and has raised doubts about the pharmaceutical giant's performance. While GSK has been a reliable dividend payer in the past, experts are recommending caution due to this recent development. To make an informed decision, investors are encouraged to seek advice from professional stock market analysts, such as Stocks Prognosis, who can offer insights into the predicted movement of GSK's shares. By staying updated with expert opinions, investors can navigate potential risks and make sound investment decisions.

Find out how the GSK PLC rate is expected to change

Get Forecast for GSK

Investor opinions & comments:

I trust GSK's track record as a reliable dividend payer, so I'm not too concerned about this bet by Citadel. I believe GSK will continue to perform well in the long run
— from ProfitPaul at 02-23-2025 06:48
This news about Citadel betting against GSK is concerning. I'll definitely keep an eye on how this plays out in the stock market
— from WealthyWill at 02-23-2025 00:10
Citadel's move has certainly raised doubts, but I still believe in GSK's potential. I'll be monitoring the situation closely and considering the advice of experts before making any investment decisions
— from DividendDiane at 02-22-2025 11:39
I'm not so sure about this bet against GSK. Citadel has made some risky moves in the past, and it's possible they could be making a mistake with this one
— from LauraAnderson at 02-21-2025 18:54
I wonder what specific concerns Citadel has about GSK's future prospects. It's always interesting to see hedge fund managers take such bold positions
— from AmandaWright at 02-21-2025 18:30
I'm confident that GSK will overcome this challenge. The company has a strong market presence and a history of success. I trust that GSK's management will navigate through any obstacles and continue to deliver returns for investors
— from MeganMason at 02-20-2025 13:09
I have confidence in GSK's pharmaceutical portfolio and its ability to innovate. This bet by Citadel may just be an opportunity for GSK to prove its critics wrong
— from MatthewGarcia at 02-20-2025 10:36
I'd like to know more about the reasoning behind Citadel's bearish position on GSK. Without that information, it's hard to judge the validity of this bet
— from AnthonyBennett at 02-20-2025 04:50
If you want to leave a comment, then you need Login or Register





Other news for GSK

GSKMarch 21, 2025GSK Lead Plaintiff Deadline Approaching - Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action  ~2 min.

GSK PLC, a global pharmaceutical company, is facing a class action lawsuit....

GSKMarch 19, 2025GSK Faces Class Action Lawsuit and Upcoming Deadlines - Investors Beware!  ~2 min.

Global pharmaceutical company, GSK PLC, is currently facing a class action lawsuit, with upcoming deadlines for affected investors to be aware of....

GSKMarch 15, 2025Shareholders that lost money on GSK plc GSK Urged to Join Class Action  ~2 min.

GSK plc, also known as GlaxoSmithKline, is facing a potential class action lawsuit from shareholders who have suffered financial losses....

GSKMarch 14, 2025Glaxo GSK Up 8 Since Last Earnings Report: Can It Continue?  ~2 min.

GlaxoSmithKline (GSK) has been experiencing positive growth since its last earnings report, with stock prices soaring by 8%. This has left investors intrigued, wondering if this upward trend will continue....

GSKFebruary 28, 2025GSK plc Successfully Delivers on Pipeline Plans, Analysts Recommend Buying Stocks  ~2 min.

GSK plc, a leading pharmaceutical company, has recently impressed the market with its success in delivering on pipeline plans....



Related news

VRTXJanuary 2, 2025Vertex Pharmaceuticals Incorporated: Promising Future Ahead  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is gaining attention in the options market, with predictions of a potential spike in its stock. Brokerages have set a price target of $494....

VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....

VRTXJanuary 29, 2025Brighton Jones LLC Increases Stake in Vertex Pharmaceuticals VRTX  ~1 min.

Brighton Jones LLC, a prominent investment firm, has recently revealed that it has increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)....

VRTXJanuary 1, 2025Exciting Growth Predicted for Vertex Pharmaceuticals VRTX: Expert Analysis  ~1 min.

According to recent reports, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is predicted to experience significant growth in the near future....

VRTXFebruary 10, 2025Vertex Pharmaceuticals Announces Breakthrough FDA Approval  ~1 min.

Vertex Pharmaceuticals has recently received a major FDA approval for its groundbreaking drug. This approval is expected to have a significant impact on the company's future and its stock value....